VALN - Valneva SE - ADR
IEX Last Trade
7.32
-0.020 -0.273%
Share volume: 6,857
Last Updated: Fri 30 Aug 2024 09:51:44 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$7.34
-0.02
-0.27%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-5.67%
1 Month
1.67%
3 Months
-17.75%
6 Months
0.28%
1 Year
-47.90%
2 Year
-60.86%
Key data
Stock price
$7.32
DAY RANGE
N/A - N/A
52 WEEK RANGE
$6.39 - $14.94
52 WEEK CHANGE
-$0.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Thomas Lingelbach
Region: US
Website: https://valneva.com/
Employees: 700
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://valneva.com/
Employees: 700
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.
Recent news